Business Wire

Actus Nutrition Acquires Protein Facility from Foremost Farms USA

28.4.2025 19:30:00 CEST | Business Wire | Press release

Share

Deal includes exclusive long-term whey protein supply agreement

Actus Nutrition (“Actus”), a leading vertically-integrated nutritional ingredients manufacturer and portfolio company of Butterfly Equity (“Butterfly”), today finalized an agreement to purchase a 99,000 sq. ft. processing facility from Foremost Farms USA (“Foremost Farms”). The facility, located in Sparta, WI, currently manufactures whey protein products, which Actus will continue producing at the location. As part of the deal, Actus and Foremost Farms will begin a long-term exclusive, network wide whey protein partnership supporting growth for both organizations. Actus plans to invest significant capital into the facility to increase capacity and expand its capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428226854/en/

Sparta, WI Facility

“We’ll be able to hit the ground running because we can plug the Sparta facility into our existing manufacturing network without a lot of changes,” said David Lenzmeier, CEO of Actus Nutrition. “The facility will provide added capacity that will help us better meet the insatiable global demand for whey protein, while further positioning Actus to meet the needs of our existing customers.”

“Foremost Farms and Actus have a strong relationship that goes back many years, and this extends our partnership in new directions,” said Declan Roche, Chief Commercial Officer for Foremost Farms USA. “This scenario creates a win-win, enabling Foremost Farms to streamline its operations while continuing to maximize value for the cooperative members through a long-term strategic partner.”

The Sparta location is the company’s seventh manufacturing facility in Wisconsin. Actus also operates manufacturing sites in Minnesota, Nebraska, California, Idaho, and Illinois. Actus plans to extend offers of employment to the current active team members at the facility as part of its launch under new ownership. Additional hiring is anticipated to support operational needs and future growth. The parties expect to close the acquisition before the end of May.

“We are pleased that this sale will allow Foremost Farms to continue to focus on its core business,” said Joel Eigenbrood, Chairman of the Board of Directors for Foremost Farms USA. “We appreciate the contributions made by our Sparta employees and we look forward to working with Actus to create more value for our patron farmers.”

About Actus Nutrition®

Actus Nutrition is a manufacturer of nutritional ingredients for the health and wellness, performance nutrition and functional food industries, with facilities in WI, MN, NE, IL, ID and CA. The core of Actus Nutrition’s business is in high protein ingredients (whey protein concentrates, isolates and hydrolysates, as well as milk protein concentrates, isolates and micellar casein), lactose and permeate as well as value added ingredients such as lactoferrin. Actus Nutrition also has a significant presence within the pet and livestock feed industries. Additional information about Actus Nutrition can be found at Actus.com.

About Foremost Farms USA®

Foremost Farms USA® is a dairy cooperative representing hundreds of Midwest dairy farmer members located across seven Midwest states, including Illinois, Indiana, Iowa, Michigan, Minnesota, Ohio and Wisconsin – America’s Dairyland. It is one of the largest, leading dairy cooperatives in the United States and a major food manufacturing business.

About Butterfly

Butterfly is a Los Angeles, California-based private equity firm that invests exclusively in the $26 trillion food sector. Butterfly is a leading “seed to fork” food ecosystem investor in North America and seeks to generate consistent investment returns through deep sector expertise, a data-driven investment process, and an operations-driven approach to value creation. Since its founding in 2016, the firm has invested in a diverse portfolio of category-leading businesses representing approximately $8 billion in enterprise value including The Duckhorn Portfolio, Rise Baking Company, Actus Nutrition, Chosen Foods, MaryRuth Organics, Pete and Gerry’s, Orgain, Generous Brands, Bolthouse Fresh Foods, QDOBA, and Pacifico Aquaculture. To learn more, please visit https://www.bfly.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250428226854/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release

Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis

Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release

Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment

OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release

NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi

Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release

Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye